BIIB
Biogen Inc. · NASDAQ
- Sector Health Technology
- Industry Pharmaceuticals: Major
- Website biogen.com
- Employees(FY) 8725
- ISIN US09062X1037
Performance
+3.6%
1W
+13.7%
1M
-7.93%
3M
+0.24%
6M
-12.92%
YTD
-27.75%
1Y
Profile
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It also provides RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, immunology related diseases, neurovascular disorders, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. Biogen Inc. has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Investment Analysis Report: Biogen Inc. (BIIB)
Overview
Biogen Inc. (BIIB) operates in the Health Technology sector, specifically in the Pharmaceuticals: Major industry. The company has a market capitalization of $32.46 billion. In this report, we will conduct a comprehensive analysis of BIIB's financial health, valuation, earnings and revenue g...
Technical Analysis of BIIB 2024-05-10
Overview:
In analyzing the technical indicators for BIIB over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement. By examining these key aspects, we aim to offer valuable insights and predictions for the upcoming days.
Trend Analysis:
...Recent News & Updates
- 2024-05-10 22:11
- 2024-05-10 20:00
- 2024-05-09 03:15
- 2024-05-08 18:30
The 3 Most Undervalued Pharma Stocks to Buy in May 2024(Investorplace)
- 2024-05-08 14:01
- 2024-05-08 09:40
- 2024-05-08 07:01
Q1 2024 Abcellera Biologics Inc Earnings Call(Thomson Reuters StreetEvents)
- 2024-05-04 22:27
Morgan Stanley's Top 15 Stock Picks for 2024(Insidermonkey)
- 2024-05-04 10:27
Morgan Stanley’s Top 15 Stock Picks for 2024(Insider Monkey)
- 2024-05-03 12:01
- 2024-05-02 07:30
- 2024-05-01 19:30
- 2024-05-01 09:50
- 2024-04-29 22:03
7 Retirement Stocks to Buy at a 52-Week Low in April(Investorplace)
- 2024-04-29 21:50
10 Most Promising Stocks to Buy Before They Take Off(Insidermonkey)
- 2024-04-29 10:03
7 Retirement Stocks to Buy at a 52-Week Low in April(InvestorPlace)
- 2024-04-29 09:50
10 Most Promising Stocks to Buy Before They Take Off(Insider Monkey)
- 2024-04-28 09:26
- 2024-04-27 08:56
- 2024-04-26 11:27
- 2024-04-26 11:27
- 2024-04-26 08:25
- 2024-04-26 04:05
- 2024-04-26 02:15
Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript(Insidermonkey)
- 2024-04-26 01:02
Decoding Biogen Inc (BIIB): A Strategic SWOT Insight(GuruFocus.com)
- 2024-04-25 17:00
- 2024-04-25 16:05
- 2024-04-25 14:28
- 2024-04-25 14:15
Biogen Inc. (NASDAQ:BIIB) Q1 2024 Earnings Call Transcript(Insider Monkey)
- 2024-04-25 10:52
Page 1 of 10
previousnext